Date published: 2026-5-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

VSIG (V-set and immunoglobulin domain containing) Inhibitors

The V-set and Immunoglobulin Domain Containing (VSIG) family is a group of proteins characterized by the presence of V-set and immunoglobulin (Ig) domains. These domains are typically found in molecules involved in immune system functioning and cell adhesion. This family is currently comprised of eight members, including VSIG1, VSIG2, VSIG3, VSIG4, VSIG8, VSIG9, VSIG10, and VSIG10 L, which are all type I transmembrane proteins. Members of the VSIG family are predominantly expressed in the immune system and various epithelial tissues, suggesting a role in immune responses and epithelial cell interactions. The function of VSIG proteins often involves cell-cell adhesion, signaling, and modulation of immune responses, although the specific roles can vary among different family members. In terms of signaling, VSIG proteins are known to participate in a variety of pathways, including those that regulate cell proliferation, differentiation, and apoptosis, particularly in the context of immune and epithelial cells. Furthermore, some VSIG family members have been implicated in the development and progression of certain cancers, indicating their potential as targets or biomarkers in oncology.

Targeting V-set and Immunoglobulin Domain Containing (VSIG) proteins using small molecules can provide valuable insights into the mechanistic aspects of T-cell responses and immune suppressive microenvironments. VSIG proteins are implicated in immune cell interactions and signaling pathways that are crucial for the regulation of T-cell activity and immune tolerance. By disrupting or inhibiting VSIG proteins, researchers can observe changes in T-cell behavior, helping to elucidate their role in immune activation and suppression.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

AZD7762

860352-01-8sc-364423
2 mg
$107.00
(1)

A potent inhibitor of both CHK1 and CHK2, used in preclinical studies for cancer. Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

MEK inhibitor, could interfere with VSIG-related MAPK/ERK signaling pathways.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor, potentially affecting VSIG-related stress response pathways.

LY2606368

1234015-52-1sc-507521
sc-507521A
sc-507521B
sc-507521C
sc-507521D
sc-507521E
5 mg
10 mg
25 mg
100 mg
1 g
10 g
$176.00
$300.00
$500.00
$1900.00
$8000.00
$25000.00
(0)

A selective CHK1 inhibitor, being investigated in clinical trials for various types. Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

p38 MAPK inhibitor, could modify VSIG-related inflammatory response pathways.

PF 477736

952021-60-2sc-362781
sc-362781A
5 mg
25 mg
$115.00
$431.00
(1)

A potent and selective CHK1 inhibitor Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role.

SCH 900776

891494-63-6sc-364611
sc-364611A
5 mg
10 mg
$255.00
$338.00
(0)

A selective CHK1 inhibitor, has been investigated in clinical trials Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role.